全球标靶 DNA RNA定序市场

预计到 2030 年，全球标靶 DNA RNA定序市场规模将达到 314 亿美元

全球标靶DNA/RNA定序市场规模预计在2024年为117亿美元，预计2030年将达到314亿美元，2024年至2030年的复合年增长率为17.9%。作为本报告分析的细分市场之一，NGS预计将以15.8%的复合年增长率在分析期结束时达到170亿美元。其余产品细分市场在分析期间的复合年增长率预计为20.7%。

美国市场规模估计为 32 亿美元，中国市场预期复合年增长率为 23.2%

美国的目标DNA RNA定序市场规模预计在2024年达到32亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到69亿美元，在2024-2030年的分析期间内，复合年增长率为23.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为13.5%和16.0%。在欧洲，预计德国市场的复合年增长率约为14.2%。

全球靶向 DNA RNA定序市场—主要趋势和驱动因素摘要

为什么标靶 DNA RNA定序优于全基因组和转录组方法？

在精准医疗和高通量基因组学时代，标靶DNA和RNA定序已成为全基因组和转录组定序的实用且高效的替代方案。透过聚焦于特定的基因组区域或感兴趣的转录本子集，该方法提供了一种经济高效、可扩展且具有临床应用价值的方法来探讨遗传变异、表现图谱和分子生物标记。与会产生大量无关数据并需要大量计算资源的全基因组定序不同，标靶定序使研究人员和临床医生能够识别与疾病路径相关的已知基因、调控元件和突变热点。例如，在肿瘤学领域，标靶化定序panel使临床医生能够以更快的周转时间和更好的可解释性识别癌症相关基因中的可操作突变。在感染疾病研究中，标靶RNA定序能够分析病原体特异性转录本，有助于菌株辨识和抗药性分析。此外，遗传疾病诊断、药物基因组学和免疫组库分析越来越依赖标靶检测来获得准确且可重复的见解。随着医疗保健和生命科学行业寻求临床可操作、时间敏感的基因数据，靶向测序方法正在弥合研究与临床实用之间的差距，提供回答高影响生物学问题所需的深度和特异性，而不会产生过多数据噪音的负担。

技术创新如何提高标靶定序的效率和准确性？

定序化学、探针设计、扩增通讯协定和生物资讯学的进步显着提高了靶向 DNA 和 RNA 定序的灵敏度、特异性和通量。杂交捕获和基于扩增子的富集等技术变得更加复杂，可以精确定位低频变异和结构复杂的基因组区域。自我调整采样技术可以在奈米孔定序平台上进行即时目标选择，减少浪费的读取并提高效率。多路復用文库製备试剂套件和自动化友好的工作流程加快了周转时间并减少了样品处理错误，而低套件和兼容 FFPE 的套件则扩展了临床和劣化样品的效用。在数据分析方面，整合的生物资讯流程和人工智慧驱动的变异调用器提高了读取映射、突变检测和转录本定量的可信度，即使在难以定序的区域也是如此。云端基础的平台正在促进临床实验室的协作、安全资料储存和简化报告。此外，双DNA/RNA面板的开发使得从单一样本进行基因组和转录组综合分析成为可能，这对于肿瘤学和免疫分析应用尤其有用。再加上更高的读取精度、更快的定序仪和更便宜的试剂组，这些创新使得标靶定序不仅成为一种主流技术，更成为一种技术成熟、可广泛部署的精准诊断和转化研究解决方案。

标靶 DNA RNA定序正在哪些领域被应用以及出现了哪些使用案例？

标靶DNA和RNA定序已广泛应用于临床、学术和工业领域，其应用范围远远超出了传统的基因组研究。在临床肿瘤学领域，标靶定序组现已成为固态肿瘤和骨髓恶性肿瘤的常规检测，有助于识别可操作的突变、指南治疗选择和监测微小残留病灶。在生殖健康和罕见疾病诊断领域，标靶检测能够快速筛检特定基因集中的致病变异，从而提高诊断率，同时降低成本并缩短週转时间。在感染疾病研究中，病原体特异性RNA定序正被用于快速识别新变异、抗菌素抗药性标记以及对治疗的转录反应。在免疫学和疫苗开发领域，标靶T细胞和B细胞受体定序正被用于研究免疫组库和反应动力学。在医疗保健领域之外，农业基因组学研究人员正在使用靶向定序分析植物和牲畜的性状；而在环境监测领域，RNA组有助于追踪生态系统和工业反应器中的微生物活动。药物开发平臺越来越多地将标靶定序用于生物标记发现和伴随诊断开发。从地区来看，临床基因组学较为成熟的北美和西欧地区应用强劲，而亚太地区则由于研究资金的增加、基因组学生态系统的兴起以及政府在精准医疗方面的倡议而呈现快速增长。随着定序仪的可携式增强和数据分析的便利性，学术和诊断领域的中小型实验室也开始采用针对性方法，从而扩大了市场覆盖范围并丰富了使用案例的多样性。

是什么推动了全球标靶 DNA RNA定序市场加速成长？

标靶DNA RNA定序市场的成长是由临床需求、研究重点、成本效益和快速技术成熟度等因素共同推动的。全球慢性病和癌症发生率的上升以及对个人化医疗的兴趣，推动了对快速、可操作的基因洞察的需求，而标靶定序仪正是实现这一目标的理想之选。与全基因组方法相比，标靶化方法显着降低了定序成本，降低了数据复杂性，并缩短了报告时间，使其更易于用于常规诊断，尤其是在资源受限的环境中。多组体学策略的整合以及人们对空间和单细胞测序日益增长的兴趣，进一步推动了相关技术的采用，因为研究人员正在寻求将高通量准确性与数据相关性相结合的方法。标靶化NGS定序面板在临床应用（尤其是在肿瘤学、药物基因组学和遗传疾病领域）的监管核准，正在检验这些方法的效用并加速其临床部署。基因组学研究资金筹措的增加，加上政府针对国家定序计划和生物样本库建设的倡议，正在拓宽其基础设施和支持生态系统。学术机构、生物技术公司和诊断实验室之间的伙伴关係正在推动针对特定人群和疾病的专科检测组合的创新和商业化。同时，自动化、使用者友善的NGS平台和整合分析软体的普及，正在使中型和分散式实验室的可近性更加普及。随着分子诊断和转化研究对准确性、速度和经济性的需求日益增长，靶向DNA RNA定序将在塑造下一代基因组医学方面发挥越来越重要的作用。

部分

产品（NGS、其他）、工作流程（预测序、定序、数据）、类型（基于 DNA 的标靶定序、基于 RNA 的标靶定序）、应用（人类生物医学研究、植物与动物科学、药物发现、其他）、最终用途（学术研究、医院与诊所、製药与生物技术公司、其他）

受访公司范例

• Agilent Technologies, Inc.
• Azenta Life Sciences（GENEWIZ）
• BGI Genomics
• Bio-Rad Laboratories, Inc.
• CD Genomics
• Element Biosciences
• F. Hoffmann-La Roche Ltd
• Genomatix Software GmbH
• GeneDx
• HudsonAlpha Institute for Biotechnology
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• New England Biolabs
• Novogene Corporation
• Nugen Technologies, Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Paragon Genomics
• PerkinElmer, Inc.
• PierianDx
• QIAGEN NV

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 并未遵循典型的 LLM 或特定产业的 SLM查询，而是建立了一个从全球专家收集的内容库，其中包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Targeted DNA RNA Sequencing Market to Reach US$31.4 Billion by 2030

The global market for Targeted DNA RNA Sequencing estimated at US$11.7 Billion in the year 2024, is expected to reach US$31.4 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. NGS, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Other Products segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 23.2% CAGR

The Targeted DNA RNA Sequencing market in the U.S. is estimated at US$3.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 23.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.5% and 16.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Global Targeted DNA RNA Sequencing Market - Key Trends & Drivers Summarized

Why Is Targeted DNA RNA Sequencing Gaining Ground Over Whole Genome and Transcriptome Approaches?

In the era of precision medicine and high-throughput genomics, targeted DNA and RNA sequencing has emerged as a practical and efficient alternative to whole genome and transcriptome sequencing. By focusing on specific genomic regions or transcript subsets of interest, this method offers a highly cost-effective, scalable, and clinically relevant way to interrogate genetic variation, expression profiles, and molecular biomarkers. Unlike whole genome sequencing, which can generate enormous amounts of irrelevant data and require intensive computational resources, targeted sequencing enables researchers and clinicians to zero in on known genes, regulatory elements, or mutation hotspots linked to disease pathways. In oncology, for example, targeted sequencing panels allow clinicians to identify actionable mutations across cancer-relevant genes with faster turnaround and better interpretability. In infectious disease research, targeted RNA sequencing enables pathogen-specific transcript analysis, aiding in strain identification and drug resistance profiling. Additionally, hereditary disease diagnostics, pharmacogenomics, and immune repertoire profiling are increasingly reliant on targeted assays for precise, repeatable insights. As the healthcare and life sciences industries seek clinically actionable, time-sensitive genetic data, targeted sequencing methods are bridging the gap between research and clinical utility, offering the depth and specificity needed to answer high-impact biological questions without the burden of excessive data noise.

How Are Technology Innovations Enhancing the Efficiency and Accuracy of Targeted Sequencing?

Advancements in sequencing chemistry, probe design, amplification protocols, and bioinformatics are driving significant improvements in the sensitivity, specificity, and throughput of targeted DNA and RNA sequencing. Techniques such as hybrid capture and amplicon-based enrichment are becoming more refined, enabling accurate targeting of low-frequency variants and structurally complex genomic regions. Adaptive sampling technologies now allow for real-time target selection on nanopore sequencing platforms, reducing wasted reads and increasing efficiency. Multiplexed library preparation kits and automation-friendly workflows are cutting down turnaround times and reducing sample handling errors, while low-input and FFPE-compatible kits are expanding usability in clinical and degraded samples. On the data analysis front, integrated bioinformatics pipelines and AI-powered variant callers are enhancing the reliability of read mapping, mutation detection, and transcript quantification, even in difficult-to-sequence regions. Cloud-based platforms are facilitating collaborative research, secure data storage, and streamlined reporting for clinical labs. Furthermore, the development of dual DNA/RNA panels is supporting integrated genomic and transcriptomic profiling from a single sample, which is particularly useful in oncology and immune profiling applications. Combined with increasing read accuracy, faster sequencers, and more affordable reagent kits, these innovations are making targeted sequencing not just a focused method, but a technically sophisticated and widely deployable solution for precision diagnostics and translational research.

Where Is Targeted DNA RNA Sequencing Being Adopted, and What Are the Emerging Use Cases?

Targeted DNA and RNA sequencing is being adopted across a wide range of clinical, academic, and industrial settings, with applications extending well beyond traditional genomics research. In clinical oncology, targeted sequencing panels are now routine for solid tumors and hematologic malignancies, helping identify actionable mutations, guide therapy selection, and monitor minimal residual disease. In reproductive health and rare disease diagnostics, targeted assays enable rapid screening for pathogenic variants across defined gene sets, improving diagnostic yield while reducing costs and turnaround times. In infectious disease research, pathogen-specific RNA sequencing is being used for rapid identification of emerging variants, antimicrobial resistance markers, and transcriptional responses to therapeutic agents. The immunology and vaccine development fields are leveraging targeted T-cell and B-cell receptor sequencing to study immune repertoires and response dynamics. Beyond healthcare, agrigenomics researchers use targeted sequencing to analyze plant and livestock traits, while in environmental monitoring, RNA panels help track microbial activity in ecosystems and industrial bioreactors. Drug development pipelines are increasingly incorporating targeted sequencing for biomarker discovery and companion diagnostic development. Geographically, adoption is strong in North America and Western Europe, where clinical genomics is more mature, while Asia-Pacific is witnessing rapid growth driven by expanding research funding, genomics startup ecosystems, and government initiatives in precision medicine. With sequencing instruments becoming more portable and data analysis more accessible, small to mid-sized labs in academia and diagnostics are also embracing targeted methods, expanding market reach and diversity of use cases.

What’s Fueling the Accelerated Growth of the Global Targeted DNA RNA Sequencing Market?

The growth of the targeted DNA RNA sequencing market is being driven by the convergence of clinical demand, research prioritization, cost-efficiency, and rapid technological maturation. The global rise in chronic diseases, cancer incidence, and interest in personalized medicine is increasing demand for quick, actionable genetic insights that targeted sequencing is well-equipped to provide. Compared to whole genome approaches, targeted methods offer significantly lower sequencing costs, reduced data complexity, and faster reporting timelines-making them more accessible for routine diagnostics, especially in resource-constrained settings. The integration of multi-omic strategies and growing interest in spatial and single-cell sequencing are further fueling adoption, as researchers seek ways to combine high-throughput precision with data relevance. Regulatory approvals of targeted NGS panels for clinical use, especially in oncology, pharmacogenomics, and inherited diseases, are validating the utility of these approaches and accelerating clinical deployment. Rising funding in genomics research, coupled with government initiatives aimed at national sequencing projects and biobank development, is broadening the infrastructure and support ecosystem. Partnerships between academic institutions, biotech firms, and diagnostic labs are fostering innovation and commercialization of specialized panels tailored for specific populations or diseases. At the same time, the availability of automated, user-friendly NGS platforms and integrated analysis software is democratizing access for mid-sized and decentralized laboratories. As demand for precision, speed, and affordability grows in molecular diagnostics and translational research, targeted DNA RNA sequencing is positioned to play an increasingly central role in shaping the next generation of genomic medicine.

SCOPE OF STUDY:

The report analyzes the Targeted DNA RNA Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (NGS, Others); Workflow (Pre-sequencing, Sequencing, Data); Type (DNA-based Targeted Sequencing, RNA-based Targeted Sequencing); Application (Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, Others); End-Use (Academic Research, Hospitals & Clinics, Pharma & Biotech Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Agilent Technologies, Inc.
• Azenta Life Sciences (GENEWIZ)
• BGI Genomics
• Bio-Rad Laboratories, Inc.
• CD Genomics
• Element Biosciences
• F. Hoffmann-La Roche Ltd
• Genomatix Software GmbH
• GeneDx
• HudsonAlpha Institute for Biotechnology
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• New England Biolabs
• Novogene Corporation
• Nugen Technologies, Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Paragon Genomics
• PerkinElmer, Inc.
• PierianDx
• QIAGEN N.V.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Targeted DNA RNA Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Demand for Actionable Genetic Insights Throws the Spotlight on Targeted DNA RNA Sequencing in Clinical Diagnostics
  • Rising Adoption of Precision Medicine Approaches Propels Use of Focused Sequencing Panels in Oncology and Rare Disease Detection
  • Increased Interest in Transcriptomic Profiling Strengthens the Business Case for Targeted RNA Sequencing in Gene Expression Analysis
  • Integration of Sequencing into Routine Clinical Workflows Drives Adoption of Rapid and Cost-Effective Targeted Approaches
  • Advancements in Probe Design and Library Preparation Technologies Generate Higher Accuracy and Efficiency in Targeted Assays
  • Expansion of Liquid Biopsy Applications Accelerates Demand for Highly Sensitive Targeted Sequencing in Minimal Residual Disease Monitoring
  • Growing Utility in Infectious Disease and Pathogen Detection Expands the Addressable Market for Targeted Sequencing Platforms
  • Supportive Reimbursement Policies and Regulatory Approvals Spur Clinical Adoption of Targeted Genomic Tests
  • Emergence of Single-Cell and Spatial Genomics Drives Integration of Targeted Approaches in Multi-Omic Workflows
  • Use of AI and Machine Learning in Variant Calling Enhances Interpretation Accuracy and Streamlines Bioinformatics Pipelines
  • Decentralization of Genomic Testing Drives Adoption of Targeted Sequencing in Mid-Sized and Regional Laboratories
  • Rising Demand for Companion Diagnostics in Oncology and Pharmacogenomics Fuels Development of Targeted Gene Panels
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Targeted DNA RNA Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Targeted DNA RNA Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Human Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Human Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Human Biomedical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Plant & Animal Sciences by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Plant & Animal Sciences by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Plant & Animal Sciences by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pre-sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pre-sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Pre-sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for DNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for DNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for DNA-based Targeted Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for RNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for RNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for RNA-based Targeted Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• JAPAN
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• CHINA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 95: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• EUROPE
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Targeted DNA RNA Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• FRANCE
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 128: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: France 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 137: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 140: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: France Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: France 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• GERMANY
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 149: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Germany Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 152: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Germany Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 155: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Germany Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 161: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Italy Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 164: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Italy Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 167: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Italy Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 170: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Italy Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 173: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: UK Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 176: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: UK Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 179: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: UK Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: UK 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 182: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: UK Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 185: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: UK Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 188: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Spain Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 191: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Spain Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 194: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Spain Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 197: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Spain Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 200: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Spain Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 203: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Russia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 206: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Russia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 209: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Russia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 212: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Russia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 215: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Russia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 251: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Australia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 254: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Australia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 257: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Australia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 260: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Australia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 263: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Australia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• INDIA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 266: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: India Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: India 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 269: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: India Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: India 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 272: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: India Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: India 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 275: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: India Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: India 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 278: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: India Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: India 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 281: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: South Korea Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 284: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: South Korea Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 287: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: South Korea Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 290: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: South Korea Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 293: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: South Korea Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 311: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 312: Latin America Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 314: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Latin America Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 317: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Latin America Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 320: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Latin America Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 323: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Latin America Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 326: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Latin America Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 329: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Argentina Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 332: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Argentina Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 335: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Argentina Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 338: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Argentina Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 341: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Argentina Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 344: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Brazil Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 347: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Brazil Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 350: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Brazil Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 353: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Brazil Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 356: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Brazil Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 359: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Mexico Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 362: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Mexico Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 365: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Mexico Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 368: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Mexico Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 371: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Mexico Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 389: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 390: Middle East Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 392: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Middle East Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 395: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Middle East Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 398: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Middle East Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 401: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Middle East Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 404: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Middle East Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 407: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Iran Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 410: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Iran Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 413: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Iran Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 416: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Iran Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 419: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Iran Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 422: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Israel Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 424: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 425: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Israel Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 427: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 428: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Israel Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 430: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 431: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Israel Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 433: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 434: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Israel Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 436: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 439: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 442: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 445: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 448: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 451: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 452: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: UAE Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 454: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 455: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: UAE Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 457: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 458: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: UAE Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 460: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 461: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: UAE Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 463: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 464: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: UAE Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 466: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 469: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 472: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 475: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 478: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 481: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• AFRICA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 482: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Africa Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 484: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 485: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Africa Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 487: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 488: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Africa Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 490: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 491: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Africa Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 493: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 494: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Africa Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 496: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION